Stock AnalizCaris Life Sciences, Inc. CAI
Medical Specialities · IPO 2025 · data as of November 13, 2026
Caris Life Sciences, Inc. (CAI) is a healthcare company listed in the US with a market value of about $6.6B. In the twelve months to September 30, 2026 it had revenue of $1.0B and net income of $96M, a net margin of 9.2%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 13.9, a price to free cash flow of 228.6, a 5-year average ROIC of 4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% below the current price.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $1.0B | $812M | $412M | $306M |
| Net income | $96M | -$68M | -$282M | -$341M |
| Free cash flow | $29M | $67M | -$254M | -$298M |
| EPS (diluted) | $1.66 | $-0.40 | $-10.66 | $-13.24 |
| Net margin | 9.2% | -8.4% | -68.4% | -111.5% |
| ROIC | — | 4.5% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $34.23, 49% above the current price; targets range from $25.00 to $38.00; the consensus rating is “Buy”; expected EPS is $0.11 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Caris Life Sciences’s P/E ratio?
About 13.9, based on the last twelve months of diluted earnings per share (forward P/E about 93.2).
Is Caris Life Sciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 77% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Caris Life Sciences pay a dividend?
Not currently.
Is Caris Life Sciences a good stock to buy?
We do not give buy or sell advice. Caris Life Sciences scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.